A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys

Biochemical and Biophysical Research Communications

Volumn 445, Issue 2, 2014, Pages 511-516

  Zhang, Ling ^a   Wang, Lin ^a   Meng, Zhiyun ^a   Gan, Hui ^a   Gu, Ruolan ^a   Wu, Zhuona ^a   Gao, Lei ^a   Zhu, Xiaoxia ^a   Sun, Wenzhong ^a   Li, Jian ^a   Zheng, Ying ^a   Dou, Guifang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Anti diabetic drug; Exendin 4; Glucagon like peptide 1; Pharmacokinetics; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; E2HSA PROTEIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; INSULIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CLAMP; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IN VITRO STUDY; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PRIORITY JOURNAL; RAT; RHESUS MONKEY;

MACACA MULATTA; RATTUS;

ANTI-DIABETIC DRUG; EXENDIN-4; GLUCAGON-LIKE PEPTIDE-1; PHARMACOKINETICS; TYPE 2 DIABETES;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MACACA MULATTA; MALE; MOLECULAR SEQUENCE DATA; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; VENOMS;

EID: 84896076107     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.02.045     Document Type: Article

References (21)

1. C.F. Deacon Therapeutic strategies based on glucagon-like peptide 1 Diabetes 53 2004 2181 2189 (Pubitemid 39145569)
2. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157 (Pubitemid 46711096)
3. J.J. Holst, T. Vilsboll, and C.F. Deacon The incretin system and its role in type 2 diabetes Mol. Cell. Endocrinol. 297 2009 127 136
4. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 214 1993 829 835 (Pubitemid 23188160)
5. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
6. S.Y. Chae, Y.G. Choi, S. Son, S.Y. Jung, D.S. Lee, and K.C. Lee The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics J. Control Release 144 2010 10 16
7. S.Y. Chae, C.H. Jin, J.H. Shin, S. Son, T.H. Kim, and S. Lee et al. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs J. Control Release. 142 2010 206 213
8. C.H. Jin, S.Y. Chae, S. Son, T.H. Kim, K.A. Um, and Y.S. Youn et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice J. Control Release 133 2009 172 177
9. Z. Gao, G. Bai, J. Chen, Q. Zhang, P.W. Pan, F. Bai, and P. Geng Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris Biosci. Biotechnol. Biochem. 73 2009 688 694
10. R.A. DeFronzo, J.D. Tobin, and R. Andres Glucose clamp technique: a method for quantifying insulin secretion and resistance Am. J. Physiol. Endocrinol. Metab. 237 1979 214 223
11. J.J. Meier, and M.A. Nauck Glucagon-like peptide 1 (GLP-1) in biology and pathology Diabetes Metab. Res. Rev. 21 2005 91 117 (Pubitemid 40467658)
12. D.J. Drucker The role of gut hormones in glucose homeostasis J. Clin. Invest. 117 2007 24 32 (Pubitemid 46048446)
13. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes The Lancet 368 2006 1696 1705 (Pubitemid 46048557)
14. M.A. Bush, J.E. Matthews, E.H. De Boever, R.L. Dobbins, R.J. Hodge, S.E. Walker, M.C. Holland, M. Gutierrez, and M.W. Stewart Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects Diabetes Obes. Metab. 11 2009 498 505
15. Julio Rosenstock, Jane Reusch, Mark Bush, Fred. Yang, and Murray Stewart Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes Diabetes Care 32 2009 1880 1886
16. V.T. Chuang, U. Kragh-hansen, and M. Otagiri Pharmaceutical strategies utilizing recombinant human serum albumin Pharm. Res. 19 2002 569 577 (Pubitemid 34553662)
17. H.C. Fehmann, J. Jiang, D. Pitt, J. Schweinfurth, and B. Goke Ligand-induced regulation of glucogan-like peptide receptor function and expression in insulin-secreting beta cells Pancreas 13 1996 273 282 (Pubitemid 26317997)
18. K.E. Mayo, L.J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D.J. Drucker Glucogan receptor family Pharmacol. Rev. 55 2003 167 194
19. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov. Today 10 2005 1451 1458 (Pubitemid 41483874)
20. D. Parkes, C. Jodka, P. Smith, S. Nayak, L. Rinehart, R. Gingerich, K. Chen, and A. Young Pharmacokinetic action of exendin-4 in the rat: comparison with glucogan-like peptide-1 Drug Dev. Res. 53 2001 260 267 (Pubitemid 33029654)
21. K.A. Scott, and T.H. Moran The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 2007 983 987